Skip to main content

Featured Content

Keeping staff healthy may be the most critical component of a New York City human-services provider's effort to maintain service for high-need groups during the COVID-19 crisis.
A longer duration of treatment with the injectable formulation of buprenorphine for opioid use disorder was associated with more favorable abstinence outcomes in a newly published study.
Public health risk is forcing addiction treatment programs to rethink their typical approaches to patient drug testing at this time.
Two addiction treatment leaders discuss the industrywide disruption from the COVID-19 crisis and how it is affecting the psyche of providers and patients.
As the U.S. population ages, Elisha Figueroa, LMSW, CPS, and Angie Jones, MSSW, of JBS International say prevention professionals will need to sharpen the focus of their messaging when working with older adults.

Meetings & Publications

Back to Top